Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression

Stomach Neoplasms Clinical Trial

Official title:

Phase II, Single-arm Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03052478
• Other study ID #: 2016-08-130
• Status: Completed
• Phase: Phase 2
• Start date: February 10, 2017
• Est. completion date: September 10, 2020

Study information

• Verified date: June 2021
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is no accepted standard therapy for patients with advanced gastric cancer who have progressed during or after second-line therapy. The role of 3rd line treatment in advanced gastric cancer has not been proven.

As a novel target of gastric cancer, SMO overexpression is chosen in this study, and the investigators plan this study to evaluate the efficacy and safety of vismodegib in gastric cancer. The doses of vismodegib are based on trials of basal cell carcinoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: September 10, 2020
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of fully informed consent prior to any study specific procedures.

2. Patients must be =20 years of age.

3. Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after 1st line or second-line therapy.

• Both fluoropyrimidine and platinum agent need to be contained in the prior chemotherapies

• Prior adjuvant or neoadjuvant therapy is counted as 1 regimen, provided that disease progression occurs within 6 months after the completion of adjuvant or neoadjuvant therapy.

• Acceptable prior chemotherapy regimens for this protocol are chemotherapy regimens that include Immune Target agent therapy. (such as a pembrolizumab, ramucirumab etc)

4. Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

5. Patients with SMO overexpression by IHC

6. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.

7. ECOG performance status 0-1.

8. Patients must have a life expectancy = 3 months from proposed first dose date.

9. Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to administration of study treatment as defined below:

• Haemoglobin =9.0 g/dL (transfusion allowed)

• Absolute neutrophil count (ANC) = 1.5 x 109/L

• White blood cells (WBC) > 3 x 109/L

• Platelet count =100 x 109/L (transfusion allowed)

• Total bilirubin = 1.5 x institutional upper limit of normal (ULN) (does not include patients with Glibert's disease)

• AST (SGOT)/ALT (SGPT) = 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be = 5x ULN

• Serum creatinine =1.5 x institutional ULN

10. Negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1. for women of childbearing potential.

11. Provision of consent for mandatory biopsy at progression (fresh frozen will be mandatory if clinically feasible)

12. Provision of archival or fresh tissue sample at baseline (fresh frozen will be mandatory if clinically feasible)

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria:

1. Are currently enrolled in, or discontinued within the last 21 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

2. Any previous treatment with Hedgehog pathway inhibitor

3. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for =5 years.

4. HER2 positive patients (defined by HER2 3+ by immunohistochemistry or HER2 SISH +)

5. Patients unable to swallow orally administered medication.

6. Treatment with any investigational product during the last 21 days before the enrollment (or a longer period depending on the defined characteristics of the agents used).

7. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 3 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates or denusomab for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment.

8. With the exception of alopecia, any ongoing toxicities (>CTCAE grade 1) caused by previous cancer therapy.

9. Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks before the enrollment.

10. Resting ECG with measurable QTcB > 480 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.

11. Patients with cardiac problem as follows: Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest , Symptomatic heart failure (NYHA grade II-IV), Prior or current cardiomyopathy, Severe valvular heart disease, Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical therapy), Acute coronary syndrome within 6 months prior to starting treatment

12. Female patients who are breast-feeding or child-bearing and Male or female patients of reproductive potential who are not employing an effective method of contraception

13. Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV) (HBV carrier is allowed)

Related Conditions & MeSH terms

• Adenocarcinoma
• Stomach Neoplasms

Intervention

Drug:
• Vismodegib 150 mg
Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul City	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR) by RECIST 1.1		6 months